Dr. J, I do not want to be unkind but a lot of people have invested considerable sums and it is important to be accurate. Both of your recent posts may give an investor pause about Kevetrin versus a competing drug.
From your first post 49893:
"ENMD 2076 appears to activate both wild type and mutant p53 in humans."
It does no such thing. None of the ENMD posters or data on their website indicates this is the case.
In your second post you say this:
"Entremed is working on developing a plan for Biomarker Driven patient selection for specific cancers and this poster clearly shows activation of p53 and have used this biomarker to guide therapy with ENMD 2076."
This is basically the gist of the ENMD effort in this poster but activation is a strong and misleading reference here too. What is really being said is that p53 will be used as a basis for developing a biomarker for what is most likely the best form of TNBC on which to use ENMD 2076, a form of breast cancer in which mut p53 causes an overexpression of p53 gene expression and protein expression. Makes sense to use p53 as the marker when it is overexpressed in a particular mutant cancerous state but that is far different than saying ENMD has anything to do with activating p53.
Entremed used Nutlin in their studies for a reason - it is the drug that activates wt p53. You will note on the poster that the more Nutlin given the better the result. The ENMD data show that knockdown of p53 mediates the effectiveness of ENMD, not the other way around. In fact, they more or less state in one cancer tested, CAL51, the absence of p53, increased the resistance to ENMD. It doesn't activate p53, it just quits working well, at least for CAL51, when p53 is not present.
I do agree and commend Georgejlls for his suggestion a while back for the combo trial for TNBC using both ENMD 2076 and Kevetrin, a combination which appears to have appeal, and which you have repeated here.
I return to Wonderland where I have yet to find a drug besides Kevetrin that tackles both wtp53 and mutp53. I will keep looking.
